Stock 688091 SHANGHAI YIZHONG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Yizhong Pharmaceutical Co., Ltd.

Equities

688091

CNE1000050F4

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-09 pm EDT 		5-day change 1st Jan Change
39.61 CNY -2.03% Intraday chart for Shanghai Yizhong Pharmaceutical Co., Ltd. +5.85% -38.11%
Apr. 30 Mainland China stocks edge lower ahead of long Labor Day holiday, Hong Kong rises RE
Apr. 29 Shanghai Yizhong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2021 2022 2023
Capitalization 1 4,748 10,043 10,130
Enterprise Value (EV) 1 3,812 8,916 8,934
P/E ratio -898 x 70.5 x 62.7 x
Yield - 0.43% 0.48%
Capitalization / Revenue 1,164,504,431 x 42,564,502 x 28,118,269 x
EV / Revenue 934,861,653 x 37,785,049 x 24,797,961 x
EV / EBITDA -187 x 76.9 x 53.4 x
EV / FCF -75.2 x 264 x 162 x
FCF Yield -1.33% 0.38% 0.62%
Price to Book 4.04 x 7.61 x 6.92 x
Nbr of stocks (in thousands) 158,277 158,277 158,277
Reference price 2 30.00 63.45 64.00
Announcement Date 3/30/22 2/28/23 4/7/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales - - - 4.078 236 360.3
EBITDA 1 -16.39 -318.1 -23.86 -20.4 115.9 167.4
EBIT 1 -20.93 -323.1 -30.03 -26.99 109.5 159.6
Operating Margin - - - -661.96% 46.4% 44.29%
Earnings before Tax (EBT) 1 -12.59 -315.2 -21.85 -9.281 149.6 186.9
Net income 1 -12.59 -315.2 -21.85 -3.997 142.9 161.6
Net margin - - - -98.03% 60.54% 44.84%
EPS 2 -0.1203 -2.934 -0.1872 -0.0334 0.9000 1.020
Free Cash Flow 1 -11.51 43.19 -15.38 -50.68 33.72 55.22
FCF margin - - - -1,242.96% 14.29% 15.33%
FCF Conversion (EBITDA) - - - - 29.09% 32.98%
FCF Conversion (Net income) - - - - 23.61% 34.18%
Dividend per Share - - - - 0.2727 0.3100
Announcement Date 7/2/21 7/2/21 7/2/21 3/30/22 2/28/23 4/7/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 163 131 47.6 936 1,128 1,196
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -11.5 43.2 -15.4 -50.7 33.7 55.2
ROE (net income / shareholders' equity) -6.14% -132% -8.59% -0.56% 11.5% 11.6%
ROA (Net income/ Total Assets) -5.9% -79.7% -7% -2.31% 5.36% 6.81%
Assets 1 213.2 395.7 312.3 172.9 2,667 2,372
Book Value Per Share 2 2.030 2.240 2.050 7.430 8.330 9.250
Cash Flow per Share 2 0.0300 0 0 0.7000 4.490 5.780
Capex 1 3.46 47.6 5 3.14 35.9 8.78
Capex / Sales - - - 77.08% 15.21% 2.44%
Announcement Date 7/2/21 7/2/21 7/2/21 3/30/22 2/28/23 4/7/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
SHANGHAI YIZHONG PHARMACEUTICAL CO., LTD. Stock Shanghai Yizhong Pharmaceutical Co., Ltd.
-38.11% 868M
MERCK KGAA Stock Merck KGaA
+7.91% 72.81B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.64% 9.13B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-10.56% 5.13B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+58.79% 4.99B
YUHAN CORPORATION Stock Yuhan Corporation
+4.07% 3.9B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-16.90% 2.48B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-26.13% 2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+19.31% 2.17B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688091 Stock
  4. Financials Shanghai Yizhong Pharmaceutical Co., Ltd.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW